gwen fyfe  oncology clinical development and strategy consultant  zoominfocom igenica biotherapeutics media center press releases igenica in the news publications media contact information katie engleman pure communications inc katiepurecommunicationsinccom  back to articles igenica appoints oncology expert and industry veteran gwen a fyfe md to board of directors burlingame calif – december   – igenica inc a company focused on the discovery and development of innovative antibodies and antibodydrug conjugates adcs for the treatment of cancer today announced the appointment of oncology expert and former genentech executive gwen a fyfe md as an independent member of the company’s board of directors “gwen’s proven expertise overseeing the successful development of major oncology drugs is invaluable to igenica as we advance our pipeline and most imminently as we prepare to enter the clinic with our lead program ign in early ” said mary haakfrendscho phd chief executive officer of igenica “gwen’s appointment comes at a pivotal time in igenica’s evolution as we begin development of our first product candidate and expand our proprietary platform to accelerate the development and delivery of effective homogeneous adc therapies that have enormous potential to address critical needs of cancer patients” dr fyfe brings more than  years of drug development experience including key roles in the development and approvals of rituxan® herceptin® avastin® and tarceva® at genentech inc now a member of the roche group she served as vice president oncology development and vice president avastin franchise team she was a member of both the development oversight committee and the research review committee responsible for approving product advancement from research into clinical development dr fyfe is a globally recognized oncology expert and frequently invited member of national cancer institute working groups and grant committees american society of clinical oncologists oversight committees and institute of medicine panels she currently serves on the boards of directors of array biopharma inc and infinity pharmaceuticals inc dr fyfe is a graduate of washington university school of medicine and a boardcertified pediatric oncologist “i am very pleased to join igenica’s board of directors and have been impressed with both igenica’s platform technology and the high quality and experience of its executive team” said dr fyfe “the combination of an integrated suite of pipelineenabling capabilities and a proven team of therapeutic antibody leaders positions igenica well to drive rapid development of high impact medicines i look forward to collaborating with the igenica team to realize the mission of delivering effective biotherapeutics including adcs to patients with cancer” about igenica inc igenica inc is focused on the discovery and development of antibodies and antibodydrug conjugates adcs for the treatment of cancer igenica is the only biotherapeutic company that fully powers the adc development spectrum from a patientbased approach to target and functional antibody discovery to the generation and manufacturing of homogeneous adcs igenica’s integrated discovery engine has generated a robust pipeline of sitespecific adc candidates and functional antibodies to address critical needs of cancer patients led by a proven team of leaders with expertise in the development of therapeutic antibodies and adcs igenica is funded by a premier group of life science investors including the column group orbimed advisors am ventures and third rock ventures for more information please visit wwwigenicacom contact katie wilson pure communications inc  katiepurecommunicationsinccom a mitten road suite b burlingame ca    copyright  igenica biotherapeutics  terms of use  site map  contact gwen fyfe and norman selby join infinity pharmaceuticals  pmlive pmgroup pmecommuniquéthe directoryquality in care how to advertiseprivacy and cookies my accountregister please login to the form below not currently logged in email password i have forgotten my password pme communiqué the directory digital disruption changing the game in healthcare advanced search home news intelligence thought leadership appointments awards blogs clinical top pharma list pmhub jobs news research sales marketing regulatory healthcare jobs and recruitment trending communiqué results mixed news for pharmaspark closes on gene therapy approvalfda rejects romosozumabbiosimilars eat into jjs remicade sales gwen fyfe and norman selby join infinity pharmaceuticals will take places of james tananbaum and arnold levine who retire from board of directors usbased drug discovery and development firm infinity pharmaceuticals has appointed gwen fyfe and norman selby to its board of directorsfyfe has over  years experience in drug development including  years at genentech now part of rocheat genentech she held several senior positions including vp of its oncology development and vp of the avastin franchise team as well as avastin fyfe worked on the development teams of several other major roche drugs including rituxan herceptin and tarceva since she left genentech in  fyfe has acted as a consultant for several venture capital firms and biotech companiesselby is currently senior adviser at private equity firm perseus as well as executive chair of healthcare information company real endpointsprior to joining perseus in 0 selby was president and ceo of transform pharmaceuticals a speciality pharma company focused on innovation in the form and formulation of drug compounds which was later acquired by johnson  johnsonhis other previous roles include executive vp at citigroupciticorp from  to 00 and several senior positions at mckinsey  company where he was a senior partner including head of the firms global pharmaceuticals and medical products practiceleaving infinitys board of directors will be james tananbaum and arnold levine who are both retiring in may they had been members of infinitys board of directors since the founding of its predecessor company in 0 please enable javascript to view the comments th march  share  print friendly related hub content edelman cactus search unlimited virgo health outico pme digital edition featured jobs account manager healthcare communications £   £  bonus benefits middleweight copywriter competitive salary senior medical writer medical communications agency £   £4  benefits director of rare diseases healthcare agency london excellent package scientific director £   £  sad – ethical healthcare pr – top global agency salary tbc account manager competitive salary offered business director  healthcare advertising neg director of client services  healthcare advertising neg senior medical writer healthcare advertising home counties competitive head of healthcare – healthcare pr and communications neg senior account manager highly regarded medical communications a excellent package senior account manager account director – pharma and life scien competitive salary business unit director – strategic medical communications medco neg account executive  pharma and life sciences brighton or maccles competitive salary group account director or client services director – healthcare  £  – £  benefits project manager account manager competitive salary offered health economist office home based role award winning company up to £k principal medical writer great salary and benefits principal consultant office home based role award winning com up to £k director  client services  healthcare advertising neg senior vice president – healthcare pr  usa neg group account director healthcare advertising brand comms lon substantiel package principal medical writer – medical communications salary tbc account manager – healthcare pr – strategic comms consultancy salary tbc senior account manager account manager medical scientific communications pa excellent package pharmaceutical brand director public affairs project executive up to £k doe senior director healthcare pr home counties competitive subscribe to our email news alerts most read most shared latest content chmp backs three immunooncology drugs for solid tumourscommuniqué awards  results  communiqué awardsshock for az as mystic trial stumbles at first hurdleocrevus off to a flying start as roche raises  forecastsuk appoints pharma veteran to streamline nhs costsnice backs cancer drugs fund support for roches gazyvaro gsk’s pipeline cull claims sirukumab and possibly rare disease unitkey role for french cluster in regenerative medicine projectaudit exposes gaps in pharmas promises on trial transparencyhca appoints mike dixon as its new ceoengaging the digital healthcare professionalrandom win gold at us international film fest for medical vr pmhubadd my company any category advertising branding clinical research conferences meetings events creative and design digital communications homecare industry associations it solutions management consultancies manufacturing packaging logistics market access market research marketing consultancies media planning and buying medical communications medical education patient support and adherence pharmacy print services policy and government affairs public relations publishers recruitment and career development regulatory affairs research and development sales training translation services atlantis healthcare atlantis healthcare is a global leader in optimising patient selfmanagement established in  we design develop and implement scalable solutions latest intelligence engaging the digital healthcare professional how to plan relevant customer strategies in the digital age launching the next big thing in vascular intervention a case study by create health are patients ready for digital doctors how can technology truly benefit health delivery quick links country reports digital handbook the gallery healthcare glossary how to advertise hta guidance tracker orphan drugs and rare diseases pme supplements social media hub webinars infographics multimedia webinar customer engagement designcommuniqué awards  winners in picturescommuniqué awards  gallerypmea  winners in picturespmea  pictures about uscontact ushow to advertisesite mapall content copyright  pmgroup worldwide ltd  genentech press releases  genentech announces senior appointments in medical affairs and research search contact us about us for scientists for medical professionals for patients for media for good now hiring media  press releases attention this page may not render properly the browser you are using internet explorer  is no longer supported media inquiries 60 60 print media  press releases monday oct  0 genentech announces senior appointments in medical affairs and research south san francisco calif  october  0  genentech inc nyse dna announced today two senior appointments in the companys medical affairs and research organizations gwen fyfe md is promoted to vice president clinical hematologyoncology and kenneth hillan mb chb frcs mrcpath is promoted to vice president research operations and pathology gwen fyfe vice president clinical hematologyoncology fyfe 0 joined genentech in  as director of oncology in medical affairs and was named senior director in  while at genentech fyfe’s responsibilities have included managing the clinical trials that led to the approvals of herceptin® a humanized antibody approved for the treatment of herpositive metastatic breast cancer and rituxan® the first therapeutic antibody for nonhodgkin’s lymphoma approved in the united states in her position as vice president clinical hematologyoncology fyfe is responsible for overseeing genentech’s clinical trials in these two important areas of genentech’s business gwen has been extremely effective in driving the clinical development of genentech’s oncology pipeline said hal barron vice president of medical affairs her broad experience and strong leadership will further strengthen genentech’s clinical programs in hematology and oncology fyfe holds bachelor and medical degrees from the washington university medical school in st louis she performed residency training in pediatrics at the university of california san francisco and postdoctoral fellowship training in immunology at washington university medical school in st louis during her career fyfe has published more than  articles in peerreviewed journals kenneth hillan vice president research operations and pathology hillan  came to genentech in  to study the role of hepatocyte growth factor in liver regeneration he joined the pathology department as a scientist in  and was promoted to director of pathology in  he was named senior director of research operations in 0 in his role as vice president research operations and pathology hillan is responsible for operational management of genentech’s research organization ensuring consistent implementation of strategic objectives and improvements in research productivity he also manages the pathology department and its ongoing work in oncology immunology vascular biology and other therapeutic areas this promotion recognizes kenneth’s scientific expertise as well as his valuable contributions to shaping the strategic direction for genentech’s research organization said richard scheller phd senior vice president research hillan graduated in medicine from glasgow university in scotland in  he was named a fellow of the royal college of surgeons frcs in  and was named a member of the royal college of pathologists mrcpath in  he also is an honorary professor of molecular and therapeutic pathology at the university of leeds hillan is on the editorial advisory board of the journal of pathology and is an ad hoc reviewer for the journal of clinical pathology and the american journal of pathology and liver he has published more than  articles in peerreviewed journals about genentech genentech is a leading biotechnology company that discovers develops manufactures and commercializes biotherapeutics for significant unmet medical needs fifteen of the currently approved biotechnology products originated from or are based on genentech science genentech manufactures and commercializes ten biotechnology products directly in the united states the company has headquarters in south san francisco california and is traded on the new york stock exchange under the symbol dna    our pipeline our pipeline includes new molecular entities that address serious unmet medical needs approvals timeline a look at our approvals past and present feedback tell us what you think about our company products or website “ science is a way of thinking much more than it is a body of knowledge ” – carl sagan connect with us gwen a fyfe md  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in gwen a fyfe md board member at array biopharma inc view full profile are you gwen a fyfe md claim your profile   sign up for equilar atlas and view gwen a fyfe mds full profile with equilar atlas you can identify corporate executives in gwen a fyfe mds network and community follow changes in gwen a fyfe mds employment and moneyinmotion connect with gwen a fyfe md through your network of contacts gwen a fyfe mds executive work history current board member array biopharma inc past to view gwen a fyfe mds complete executive work history sign up now education md washington university in st louis school of medicine age 6     gwen a fyfe mds biography gwen a fyfe md has been a member of our board of directors since january 6 from  to  dr fyfe held various positions with genentech inc now a member of the roche group including vice president oncology development vice president avastin franchise team as well as the honorary title of senior staff scientist dr fyfe played an important role in the development of genentechs approved oncology agents including rituxan® herceptin® avastin® and tarceva® dr fyfe sat on the development oversight committee for all of genentechs products and participated in the research review committee that moved products from research  read more gwen a fyfe md has been a member of our board of directors since january 6 from  to  dr fyfe held various positions with genentech inc now a member of the roche group including vice president oncology development vice president avastin franchise team as well as the honorary title of senior staff scientist dr fyfe played an important role in the development of genentechs approved oncology agents including rituxan® herceptin® avastin® and tarceva® dr fyfe sat on the development oversight committee for all of genentechs products and participated in the research review committee that moved products from research into clinical development since leaving genentech in  dr fyfe has been a consultant for venture capital firms and for a variety of biotechnology companies dr fyfe currently serves as a director of array biopharma inc and previously served as a director of infinity pharmaceuticals inc dr fyfe has been an invited member of institute of medicine panels national cancer institute working groups and grant committees and american society of clinical oncologists oversight committees our corporate governance and nominating committee believes that dr fyfes qualifications for membership on the board of directors include over  years of experience in the biotechnology industry this experience allows dr fyfe to provide our board of directors with extensive industry experience in clinical development for novel oncology therapeutics dr fyfe received her ab and md from washington university school of medicine and a board certified pediatric oncologist source cascadian therapeutics inc on 6   sign up for equilar atlas and view gwen a fyfe mds full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like gwen a fyfe md more specifically youll be able to identify corporate executives in gwen a fyfe mds network and community follow changes in gwen a fyfe mds employment and moneyinmotion connect with gwen a fyfe md through your network of conections view full profile   search for over  executive profiles bio example gwen a fyfe md gwen a fyfe mds connections 4 sign up now to view gwen a fyfe mds 4 connections » ian f smith executive vice president chief operating officer and chief financial officer vertex pharmaceuticals incorporated j scott garland chief commercial officer and senior vice president relypsa inc marc tessierlavigne scientific advisor agios pharmaceuticals inc liam ratcliffe former board member edge therapeutics inc ron squarer dir and chief executive officer array biopharma inc kyle a lefkoff chairman array biopharma inc patrick y yang board member tesoro corporation r m carruthers chief financial officer and interim president alpine immune sciences inc adelene q perkins president chief executive officer and chairman of the board infinity pharmaceuticals inc david l snitman former consultant array biopharma inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith carl g annessa evp and coo hornbeck offshore services inc elon r musk ceo and chairman tesla michael c montgomery board member nmi holdings inc × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login ï¿½  equilar all rights reserved privacy policy  marshall street redwood city ca 963  phone 60   fax 60 93 microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext6 personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext9 personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft